Bio-Imaging Technologies to Exhibit at Drug Information Association's (DIA) 43rd Annual Meeting.

Meeting to Be Held on June 17-21, 2007 in Atlanta

NEWTOWN, Pa. -- Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ/NMS: BITI) today announced that it will be exhibiting at the Drug Information Association's (DIA) 43rd Annual Meeting to be held June 17-21, 2007 in Atlanta, Georgia.

The Bio-Imaging exhibit will occupy booth #1621 at the Georgia World Congress Center. The exhibition hall will be open Sunday, June 17 from 4:00 to 6:00 P.M.; Monday, June 18 from 10:00 A.M. to 6:00 P.M.; Tuesday, June 19 from 11:00 A.M. to 6:30 P.M.; and Wednesday, June 20 from 9:00 A.M. to 2:30 P.M.

About Drug Information Association

DIA is a professional association of approximately 20,000 members worldwide who are involved in the discovery, development, regulation, surveillance, or marketing of pharmaceuticals or related products.

With more than 1,000 speakers from the FDA, EMEA, and other regulatory agencies, 27 content-area tracks, and nearly 400 sessions, the presentations are geared to attendees of all experience and functional levels. The DIA Annual Meeting, above all others, offers valuable professional cross-functional learning, continuing education credits, and networking experiences. For more information visit www.diahome.org.

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands and its recent acquisition of Theralys SA in Lyon, France. Through its CapMed division, Bio-Imaging provides the Personal HealthKey[TM] technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information. Copies of Bio-Imaging Technologies' press releases and other information may be obtained through Bio-Imaging's web site at www.bioimaging.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.